| Non-Small Cell Lung Carcinoma
Alunbrig vs Augtyro
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Alunbrig vs Augtyro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAugtyro has a higher rate of injection site reactions vs Alunbrig based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Augtyro but not Alunbrig, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alunbrig
Augtyro
At A Glance
Oral
Once daily
ALK inhibitor
Oral
Once daily x14 days, then twice daily
ROS1/TRK inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Non-Small Cell Lung Carcinoma
- Solid Neoplasm
Dosing
Non-Small Cell Lung Carcinoma 90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily; may be taken with or without food.
Non-Small Cell Lung Carcinoma, Solid Neoplasm 160 mg orally once daily for 14 days, then increase to 160 mg twice daily, with or without food, until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) diarrhea, nausea, rash, cough, hypertension, fatigue, myalgia, headache, dyspnea, back pain, pruritus, edema, pyrexia, dizziness, pneumonia, arthralgia, constipation, bradycardia, abdominal pain, upper respiratory tract infection, peripheral neuropathy, stomatitis, vomiting, increased blood cholesterol
Serious ILD/pneumonitis, hypertension, bradycardia, visual disturbance, CPK elevation, pancreatic enzyme elevation, hepatotoxicity, hyperglycemia, photosensitivity
Most common (>=20%) Dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, fatigue, ataxia, cognitive impairment, muscular weakness, nausea.
Serious Pneumonia, dyspnea, pleural effusion, hypoxia.
Pharmacology
Brigatinib is a tyrosine kinase inhibitor (TKI) with activity against ALK, ROS1, IGF-1R, FLT-3, and EGFR deletion and point mutations, inhibiting ALK autophosphorylation and downstream signaling proteins (STAT3, AKT, ERK1/2, S6) in ALK-positive NSCLC cell lines and xenograft models.
Repotrectinib is a kinase inhibitor of ROS1 and tropomyosin receptor tyrosine kinases (TRKA, TRKB, TRKC); fusion proteins containing these domains drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to unconstrained cell proliferation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alunbrig
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Augtyro
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Alunbrig
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Augtyro
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Alunbrig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Augtyro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/momo
Alunbrig SMART Free Trial ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Augtyro.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AlunbrigView full Alunbrig profile
AugtyroView full Augtyro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.